FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Burger

Research Profile

Disorders

HIV Infections

Chemicals & Drugs

Living Beings

HIV-1

Procedures

Physiology

Drug Interactions

Concepts & Ideas

Co-author Network

Publications

TOP 3
Maren Blonk; Angela Colbers; Anne Poirters; Bas Schouwenberg; David Burger
Effect of ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteers.
Sandra G Heil; Jan Lindemans; Paul W Schenk; Marchina E Van Der Ende; Ilse van der Heiden; David Burger; Ron H N van Schaik
Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
C P W G M Verweij-van Wissen; Rob E Aarnoutse; David Burger; P E Verweij; R J M Brüggemann
Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Burger (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Maren Blonk; Angela Colbers; Anne Poirters; Bas Schouwenberg; David Burger
Effect of ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteers.
Antimicrobial agents and chemotherapy 2012;56(10):5070-5.
2012: Sandra G Heil; Jan Lindemans; Paul W Schenk; Marchina E Van Der Ende; Ilse van der Heiden; David Burger; Ron H N van Schaik
Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
Therapeutic drug monitoring 2012;34(2):153-9.
2012: C P W G M Verweij-van Wissen; Rob E Aarnoutse; David Burger; P E Verweij; R J M Brüggemann
Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012;887-888():79-84.
2012: Reshmie A Ramautarsing; Kiat Ruxrungtham; Jasper van der Lugt; Jiratchaya Wongsabut; David Burger; Meena Gorowara; Chuleeporn Khongpetch; Joep M A Lange; Praphan Phanuphak; Jintanat Ananworanich; Anchalee Avihingsanon
Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily.
Journal of acquired immune deficiency syndromes (1999) 2012;59(1):55-8.
2011: Reshmie A Ramautarsing; Kiat Ruxrungtham; Jasper van der Lugt; Praphan Phanuphak; Anchalee Avihingsanon; David Burger; Surasith Chaithongwongwatthana; Meena Gorowara; Stephen J Kerr; Nittaya Phanuphak
Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy.
AIDS (London, England) 2011;25(10):1299-303.
2011: David Burger; Marga Teulen; Jaco Eerland; Anneke Harteveld; Rob E Aarnoutse; Daan Touw
The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program.
Therapeutic drug monitoring 2011;33(2):239-43.
2011: Matthijs van Luin; Ferdinand W Wit; Colette Smit; Irma M Rigter; Eric J F Franssen; Clemens Richter; Frank P Kroon; Frank de Wolf; David Burger
Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands.
Therapeutic drug monitoring 2011;33(1):32-9.
2011: Serena Slavenburg; Hanneke W H A Huntjens-Fleuren; Ton S M Dofferhoff; Clemens Richter; Peter P Koopmans; CP Verwey-van Wissen; Joost P H Drenth; David Burger
Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations.
Therapeutic drug monitoring 2011;33(1):40-4.
2011: Torsak Bunupuradah; Pope Kosalaraksa; Thanyawee Puthanakit; Tawan Mengthaisong; Jiratchaya Wongsabut; Pagakrong Lumbiganon; Praphan Phanuphak; David Burger; Chitsanu Pancharoen; Jintanat Ananworanich
Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children.
AIDS (London, England) 2011;25(3):315-23.
2011: Wouter F W Bierman; David Burger; Sven A Danner; Peter Reiss; Marit G A van Vonderen; Agnes I Veldkamp; Michiel A van Agtmael
The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.
Antiviral therapy 2011;16(5):647-55.
2011: Clara T M M de Kanter; Monique Keuter; Manon J van der Lee; Peter P Koopmans; David Burger
Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir.
Antiviral therapy 2011;16(3):435-7.
2010: I M E Desar; Johanna N H Timmer-Bonte; David Burger; W T A van der Graaf; C M L van Herpen
A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
British journal of cancer 2010;103(11):1637-43.
2010: Veronica Mulenga; A Cook; A Sarah Walker; D Kabamba; C Chijoka; A Ferrier; C Kalengo; C Kityo; C Kankasa; David Burger; M Thomason; Chifumbe Chintu; Diana M Gibb
Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;51(9):1081-9.
2010: Roger J M Brüggemann; Matthijs van Luin; E P H Colbers; Myrthe W van den Dungen; Cristina Pharo; Bas J J W Schouwenberg; David Burger
Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers.
The Journal of antimicrobial chemotherapy 2010;65(10):2188-94.
2010: David Burger; Fiona Ewings; Desiré Kabamba; Rafaëlla F A L'homme; Veronica Mulenga; Chipepo Kankasa; Margaret Thomason; Diana M Gibb; Chifumbe Chintu; A Sarah Walker
Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.
Therapeutic drug monitoring 2010;32(3):369-72.
2010: C T M M de Kanter; E P H Colbers; Q Fillekes; A Hoitsma; David Burger
Pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV-infected children: a pilot study of paediatric Lopimune versus the branded product in healthy adult volunteers.
The Journal of antimicrobial chemotherapy 2010;65(3):538-42.
2010: Meena Gorowara; David Burger; Andrew Hill; Kiat Ruxrungtham
Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries.
Current opinion in HIV and AIDS 2010;5(1):90-6.
2009: Thanyawee Puthanakit; Jasper van der Lugt; Torsak Bunupuradah; Jintanat Ananworanich; Meena Gorowara; Chayapa Phasomsap; Thidarat Jupimai; Pitch Boonrak; Chitsanu Pancharoen; David Burger; Kiat Ruxrungtham
Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
The Journal of antimicrobial chemotherapy 2009;64(5):1080-6.
2009: Matthijs van Luin; Angela Colbers; CP Verwey-van Wissen; Eleonora W J van Ewijk-Beneken Kolmer; Mike van der Kolk; Arjen Hoitsma; Hugo Gomes da Silva; David Burger
The effect of raltegravir on the glucuronidation of lamotrigine.
Journal of clinical pharmacology 2009;49(10):1220-7.
2009: Matthijs van Luin; Luuk Gras; Clemens Richter; Marchina E Van Der Ende; Jan M Prins; Frank de Wolf; David Burger; Ferdinand W Wit
Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations.
Journal of acquired immune deficiency syndromes (1999) 2009;52(2):240-5.
2009: Jasper van der Lugt; Meena Gorowara; Anchalee Avihingsanon; David Burger; Jintanat Ananworanich; Kancharat Sringam; Stephen Kerr; Ferdinand W N M Wit; Joep Lange; Kiat Ruxrungtham
Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals.
AIDS (London, England) 2009;23(9):1176-9.
2009: Roger J M Brüggemann; Jan-Willem C Alffenaar; N M A Blijlevens; Eliane M Billaud; Jos G W Kosterink; Paul E Verweij; David Burger
Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(10):1441-58.
2009: Rafaëlla F A L'homme; Hanneke M J Nijland; Luuk Gras; Rob E Aarnoutse; Reinout van Crevel; Martin J Boeree; Kees Brinkman; Jan M Prins; Job R Juttmann; David Burger
Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
AIDS (London, England) 2009;23(7):863-5.
2009: A Avihingsanon; J van der Lugt; Stephen J Kerr; M Gorowara; S Chanmano; P Ohata; Joep Lange; David A Cooper; Praphan Phanuphak; David Burger; Kiat Ruxrungtham
A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults.
Clinical pharmacology and therapeutics 2009;85(4):402-8.
2009: Matthijs van Luin; Annemarie Brouwer; Andre van der Ven; Wiel de Lange; Ron van Schaik; David Burger
Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin.
AIDS (London, England) 2009;23(6):742-4.
2009: I M E Desar; David Burger; Q G C M van Hoesel; J H Beijnen; C M L Van Herpen; W T A Van der Graaf
Pharmacokinetics of sunitinib in an obese patient with a GIST.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(3):599-600.
2009: Jasper van der Lugt; Joep Lange; Anchalee Avihingsanon; Jintanat Ananworanich; Siriporn Sealoo; David Burger; Meena Gorowara; Praphan Phanuphak; Kiat Ruxrungtham
Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
Antiviral therapy 2009;14(7):1001-4.
2009: Jasper van der Lugt; Angela Colbers; Jose Molto; David Hawkins; Marchina van der Ende; Martin Vogel; Christoph Wyen; Malte Schutz; Peter P Koopmans; Kiat Ruxrungtham; Clemens Richter; David Burger
The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.
Antiviral therapy 2009;14(3):443-50.
2009: Torsak Bunupuradah; Jasper van der Lugt; Pope Kosalaraksa; Chulapan Engchanil; Pitch Boonrak; Thanyawee Puthanakit; Tawan Mengthaisong; Apicha Mahanontharit; Pisake Lumbiganon; Emily Tompkins; David Burger; Kiat Ruxrungtham; Jintanat Ananworanich
Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
Antiviral therapy 2009;14(2):241-8.
2009: Matthijs van Luin; Wendy P Bannister; Amanda Mocroft; Peter Reiss; Giovanni Di Perri; Gilles Peytavin; José Molto; Anders Karlson; Antonella Castagna; Marek Beniowski; Jens D Lundgren; David Burger
Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study.
Antiviral therapy 2009;14(1):75-83.
2009: Patricia M M B Soetekouw; M Koopman; David Burger; Vivianne C G Tjan-Heijnen; P H M De Mulder
Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma.
Acta oncologica (Stockholm, Sweden) 2009;48(1):154-6.
2009: Roger J M Brüggemann; Daan J Touw; Rob E Aarnoutse; Paul E Verweij; David Burger
International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations.
Antimicrobial agents and chemotherapy 2009;53(1):303-5.
2008: Roger J M Brüggemann; Tim Antonius; Arno van Heijst; Peter M Hoogerbrugge; David Burger; Adilia Warris
Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation.
Therapeutic drug monitoring 2008;30(6):643-6.
2008: Laura Dickinson; Marta Boffito; David J Back; Saye H Khoo; Anton L Pozniak; Peter Mugyenyi; Concepta Merry; Reshma Saskia Autar; David Burger; Leon J Aarons
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.
The Journal of antimicrobial chemotherapy 2008;62(6):1344-55.
2008: David Burger; A Huisman; N Van Ewijk; H Neisingh; P Van Uden; G A Rongen; Peter P Koopmans; R J Bertz
The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe.
Clinical pharmacology and therapeutics 2008;84(6):698-703.
2008: Rafaëlla F A L'homme; Eva P Muro; Jacqueline A H Droste; Liselotte R Wolters; Noor W J van Ewijk-Beneken Kolmer; Werner Schimana; David Burger
Therapeutic drug monitoring of nevirapine in resource-limited settings.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;47(10):1339-44.
2008: Jasper van der Lugt; Angela Colbers; David Burger
Clinical pharmacology of HIV protease inhibitors in pregnancy.
Current opinion in HIV and AIDS 2008;3(6):620-6.
2008: Carolien J P Van Den Bout-Van Den Beukel; Lydia Fievez; Meta Michels; Fred C G J Sweep; Ad R M M Hermus; Marjolein E W Bosch; David Burger; Bert Bravenboer; Peter P Koopmans; Andre J A M van der Ven
Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy.
AIDS research and human retroviruses 2008;24(11):1375-82.
2008: C J P van den Bout-van den Beukel; M van den Bos; W J G Oyen; Ad R M M Hermus; F C G J Sweep; C J J Tack; M E W Bosch; David Burger; P P Koopmans; A J A M van der Ven
The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients.
HIV medicine 2008;9(9):771-9.
2008: Roger J M Brüggemann; J Peter Donnelly; Rob E Aarnoutse; Adilia Warris; Nicole M A Blijlevens; Johan W Mouton; Paul E Verweij; David Burger
Therapeutic drug monitoring of voriconazole.
Therapeutic drug monitoring 2008;30(4):403-11.
2008: Pope Kosalaraksa; Torsak Bunupuradah; Chulapan Engchanil; Pitch Boonrak; Jintana Intasan; Pisake Lumbiganon; David Burger; Kiat Ruxrungtham; Malte Schutz; Jintanat Ananworanich
Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
The Pediatric infectious disease journal 2008;27(7):623-8.
2008: Christoph Wyen; Uwe Fuhr; D Frank; R E Aarnoutse; Tobias Klaassen; Andreas Lazar; A Seeringer; Oxana Doroshyenko; J C Kirchheiner; F Abdulrazik; Norbert Schmeisser; Clara Lehmann; W Hein; Edgar Schömig; David Burger; Gerd Fätkenheuer; Alexander Jetter
Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
Clinical pharmacology and therapeutics 2008;84(1):75-82.
2008: Carolien J P Beukel van den Bout-van den; Marjolein E W Bosch; David Burger; Peter P Koopmans; Andre J A M van der Ven
Toxic lopinavir concentrations in an HIV-1 infected patient taking herbal medications.
AIDS (London, England) 2008;22(10):1243-4.
2008: U Wintergerst; Florian Hoffmann; A Jansson; Gundula Notheis; K Huss; Michael Kurowski; David Burger
Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.
The Journal of antimicrobial chemotherapy 2008;61(6):1336-9.
2008: Carolien J P van den Bout-van den Beukel; Omar J M Hamza; Mainen J Moshi; Mecky I N Matee; Frans Mikx; David Burger; Peter P Koopmans; Paul E Verweij; Willem G E J Schoonen; Andre J A M van der Ven
Evaluation of cytotoxic, genotoxic and CYP450 enzymatic competition effects of Tanzanian plant extracts traditionally used for treatment of fungal infections.
Basic & clinical pharmacology & toxicology 2008;102(6):515-26.
2008: Tim R Cressey; Hannah Green; Saye Khoo; Jean-Marc Treluyer; Alexandra Compagnucci; Yacine Saidi; Marc Lallemant; Diana M Gibb; David Burger
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(10):1601-8.
2008: Hanneke M J Nijland; Rafaëlla F A L'homme; Gerard A Rongen; Peter van Uden; Reinout van Crevel; Martin J Boeree; Rob E Aarnoutse; Peter P Koopmans; David Burger
High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.
AIDS (London, England) 2008;22(8):931-5.
2008: David Burger; Erik S G Stroes; Peter Reiss
Drug interactions between statins and antiretroviral agents.
Current opinion in HIV and AIDS 2008;3(3):247-51.
2008: Jasper van der Lugt; Reshma Saskia Autar; Sasiwimol Ubolyam; Evian Fernandez Garcia; Jongkol sankote; Anchalee Avihingsanon; Anchalee Avihingson; Theshinee Chuenyam; David A Cooper; Joep Lange; Praphan Phanuphak; Ferdinand W N M Wit; Kiat Ruxrungtham; David Burger
Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults.
The Journal of antimicrobial chemotherapy 2008;61(5):1145-53.
2008: Jeannine F J B Nellen; M Damming; M H Godfried; Kees Boer; M E van der Ende; David Burger; Frank de Wolf; Ferdinand W N M Wit; Jan M Prins
Steady-state nevirapine plasma concentrations are influenced by pregnancy.
HIV medicine 2008;9(4):234-8.
2008: Hadewych J M ter Hofstede; Peter P Koopmans; David Burger
Stavudine plasma concentrations and lipoatrophy.
The Journal of antimicrobial chemotherapy 2008;61(4):933-8.
2008: Rafaëlla F A L'homme; Desiré Kabamba; Fiona M Ewings; Veronica Mulenga; Chipepo Kankasa; Margaret J Thomason; A Sarah Walker; Chifumbe Chintu; David Burger; Diana M Gibb
Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.
AIDS (London, England) 2008;22(5):557-65.
2008: Michiel van der Flier; Gwenda Verweel; Linda C van der Knaap; Petronette van Jaarsveld; Gert-Jan Driessen; Manon van der Lee; Nico G Hartwig; David Burger
Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily.
Antiviral therapy 2008;13(8):1087-90.
2008: Anchalee Avihingsanon; Weerawat Manosuthi; Pacharee Kantipong; Charoen Chuchotaworn; Saiyud Moolphate; Waraporn Sakornjun; Meena Gorowara; Norio Yamada; Hideki Yanai; Satoshi Mitarai; Nobukatsu Ishikawa; David A Cooper; Praphan Phanuphak; David Burger; Kiat Ruxrungtham
Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
Antiviral therapy 2008;13(4):529-36.
2007: Manon J van der Lee; Audrey A M Blenke; Gerard A Rongen; Corrien P W G M Verwey-van Wissen; Peter P Koopmans; Cristina Pharo; David Burger
Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
Antimicrobial agents and chemotherapy 2007;51(11):4098-104.
2007: Hanneke M J Nijland; Rovina Ruslami; A Juwono Suroto; David Burger; Alisjahbana Bachti; Reinout van Crevel; Rob E Aarnoutse
Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;45(8):1001-7.
2007: Jose Munoz-Moreno; Carmina R Fumaz; Maria José Ferrer; Albert Tuldrà; Tatiana Rovira; Carme Viladrich; Ramon Bayés; David Burger; Eugenia Negredo; Bonaventura Clotet
Assessing self-reported adherence to HIV therapy by questionnaire: the SERAD (Self-Reported Adherence) Study.
AIDS research and human retroviruses 2007;23(10):1166-75.
2007: Selwyn H Lowe; Elisabeth van Leeuwen; Jacqueline A H Droste; Fulco van der Veen; Peter Reiss; Joep M A Lange; David Burger; Sjoerd Repping; Jan M Prins
Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
Therapeutic drug monitoring 2007;29(5):566-70.
2007: R M M Cleijsen; M E van de Ende; F P Kroon; F Verduyn Lunel; Peter P Koopmans; Luuk Gras; Frank de Wolf; David Burger
Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
The Journal of antimicrobial chemotherapy 2007;60(4):897-900.
2007: Jan-Christian Wasmuth; I Lambertz; Esther Voigt; Martin Vogel; C Hoffmann; David Burger; Jürgen K Rockstroh
Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
European journal of clinical pharmacology 2007;63(10):901-8.
2007: Reshma Saskia Autar; Ferdinand W N M Wit; Jongkol sankote; Duanghathai Sutthichom; Elly Kimenai; Elly A M Hassink; Andrew Hill; David A Cooper; Praphan Phanuphak; Joep M A Lange; David Burger; Kiat Ruxrungtham
Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients.
AIDS (London, England) 2007;21(12):1535-9.
2007: Jan-Christian Wasmuth; E Rodermann; Esther Voigt; Martin Vogel; E Lauenroth-Mai; A Jessen; David Burger; Jürgen K Rockstroh
Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring.
European journal of medical research 2007;12(7):289-94.
2007: Pieter L A Fraaij; Gwenda Verweel; Annemarie M C van Rossum; Nico G Hartwig; David Burger; Ronald de Groot
Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment.
Infection 2007;35(3):186-9.
2007: Milly E Attema-de Jonge; David Burger; Eric J F Franssen; Kees Brinkman
Atazanavir in plasma-exchange treatment.
AIDS (London, England) 2007;21(7):884-5.
2007: David Burger; Gwenda Verweel; N Rakhmanina; C P W G M Verwey-Van Wissen; Charles J L la Porte; Alina S Bergshoeff; Hermione Lyall; Nico G Hartwig; Hannah Green; S Soldin; Diana M Gibb; Ronald de Groot
Age-dependent pharmacokinetics of lamivudine in HIV-infected children.
Clinical pharmacology and therapeutics 2007;81(4):517-20.
2007: Reshma Saskia Autar; Mark A Boyd; Ferdinand W N M Wit; Kiat Ruxrungthams; Jongkol sankote; Joep Lange; David A Cooper; Praphan Phanuphak; David Burger; Peter Reiss
Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
Antiviral therapy 2007;12(8):1265-71.
2007: Manon J van der Lee; Raaj R Sankatsing; Emile F Schippers; Martin Vogel; Gerd Fätkenheuer; Andre J A M van der Ven; Frank P Kroon; Jürgen Rockstroh; Christoph Wyen; Anselm Bäumer; Eric de Groot; Peter P Koopmans; Erik S G Stroes; Peter Reiss; David Burger
Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
Antiviral therapy 2007;12(7):1127-32.
2007: Joep J G van Oosterhout; Johnstone J Kumwenda; Mike Beadsworth; Gabriel Mateyu; Temba Longwe; David Burger; Eduard E Zijlstra
Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
Antiviral therapy 2007;12(4):515-21.
2007: Gwenda Verweel; David Burger; Nancy Sheehan; Alina S Bergshoeff; Adilia Warris; Linda C van der Knaap; Gertjan Driessen; Ronald de Groot; Nico G Hartwig
Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
Antiviral therapy 2007;12(4):453-8.
2007: Jane C Ellis; Rafaëlla F A L'homme; Fiona M Ewings; Veronica Mulenga; Frank Bell; Regina Chileshe; Elizabeth Molyneux; Julia Abernethy; Joep J G van Oosterhout; Chifumbe Chintu; A Sarah Walker; Diana M Gibb; David Burger
Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.
Antiviral therapy 2007;12(2):253-60.
2007: Rafaëlla F A L'homme; Tim Dijkema; Adilia Warris; Andre J A M van der Ven; Diana M Gibb; David Burger
Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults.
The Journal of antimicrobial chemotherapy 2007;59(1):92-6.
2006: Selwyn H Lowe; Jori Symons; Jacqueline A H Droste; Reinier W Ten Kate; Suzanne Jurriaans; David Burger; Jan C C Borleffs; Joep M A Lange; Jan M Prins
No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations.
HIV clinical trials 2006;7(6):285-90.
2006: Martijn R van der Leur; David Burger; Charles J L la Porte; Peter P Koopmans
A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults.
Therapeutic drug monitoring 2006;28(5):650-3.
2006: David Burger; S Agarwala; M Child; A Been-Tiktak; Y Wang; R Bertz
Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
Antimicrobial agents and chemotherapy 2006;50(10):3336-42.
2006: M P Hendriks; N M A Blijlevens; A V M B Schattenberg; David Burger; J Peter Donnelly
Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients.
Bone marrow transplantation 2006;38(7):521-5.
2006: Rafaëlla F A L'homme; Tim Dijkema; Andre J A M van der Ven; David Burger
Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women.
Journal of acquired immune deficiency syndromes (1999) 2006;43(2):193-6.
2006: Manon J van der Lee; Lara Dawood; Hadewych J M ter Hofstede; Marga J A de Graaff-Teulen; Eleonora W J van Ewijk-Beneken Kolmer; Nurcan Caliskan-Yassen; Peter P Koopmans; David Burger
Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects.
Clinical pharmacology and therapeutics 2006;80(2):159-68.
2006: David Burger; H Reinier Schwietert; E P H Colbers; Mark Becker
The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir.
British journal of clinical pharmacology 2006;62(2):250-2.
2006: Marthe LePrevost; Hannah Green; Jacquie Flynn; Stephen Head; Margaret Clapson; Hermione Lyall; Vas Novelli; Laura Farrelly; A Sarah Walker; David Burger; Diana M Gibb
Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.
The Pediatric infectious disease journal 2006;25(6):533-7.
2006: Mark A Boyd; Umaporn Siangphoe; Kiat Ruxrungtham; Peter Reiss; Apicha Mahanontharit; Joep M A Lange; Praphan Phanuphak; David A Cooper; David Burger
The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.
The Journal of antimicrobial chemotherapy 2006;57(6):1161-7.
2006: Mark A Boyd; David Burger; Praphan Phanuphak; David A Cooper
Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis.
AIDS (London, England) 2006;20(7):1083-5.
2006: Jolanda G M Hoefnagel; Manon J van der Lee; Peter P Koopmans; Rob Schuurman; Suzanne Jurriaans; Ard I van Sighem; Luuk Gras; Frank de Wolf; Jochem M D Galama; David Burger
The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy.
AIDS (London, England) 2006;20(7):1069-71.
2006: Charles J L la Porte; Jacqueline A H Droste; David Burger
False-positive results in urine drug screening in healthy volunteers participating in phase 1 studies with efavirenz and rifampin.
Therapeutic drug monitoring 2006;28(2):286.
2006: Heleen J van Beekhuizen; Akosua N J A de Groot; Theo M de Boo; David Burger; Nicoline Jansen; Fred K Lotgering
Sulprostone reduces the need for the manual removal of the placenta in patients with retained placenta: a randomized controlled trial.
American journal of obstetrics and gynecology 2006;194(2):446-50.
2006: David Burger; Ilse van der Heiden; Charles J L la Porte; Marchina E Van Der Ende; Paul Groeneveld; Clemens Richter; Peter P Koopmans; Frank P Kroon; Herman Sprenger; Jan Lindemans; Paul Schenk; Ron van Schaik
Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.
British journal of clinical pharmacology 2006;61(2):148-54.
2006: Hannah Green; Diana M Gibb; Alexandra Compagnucci; Vania Giacomet; Anita De Rossi; Lynda Harper; Yacine Saïdi; Guido Gattinara Castelli; Deenan Pillay; Abdel G Babiker; Jean-Pierre Aboulker; Hermione Lyall; Lee Bacheler; A Sarah Walker; Marianne Debré; Raffaella Rosso; David Burger; Marinella Della Negra; David T Dunn; Carlo Giaquinto
A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial.
Antiviral therapy 2006;11(7):857-67.
2006: Carolien J P van den Bout-van den Beukel; Peter P Koopmans; Andre J A M van der Ven; Peter A G M de Smet; David Burger
Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents.
Drug metabolism reviews 2006;38(3):477-514.
2006: Manon J van der Lee; Gwenda Verweel; Ronald de Groot; David Burger
Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
Antiviral therapy 2006;11(4):439-45.
2006: Mark A Boyd; Preeyaporn Srasuebkul; Mana Khongphattanayothin; Kiat Ruxrungtham; Elly A M Hassink; Chris Duncombe; Sasiwimol Ubolyam; David Burger; Peter Reiss; Michael Stek; Joep Lange; David A Cooper; Praphan Phanuphak
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
Antiviral therapy 2006;11(2):223-32.
2006: Jacqueline A H Droste; Brian P Kearney; Yechiel A Hekster; David Burger
Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2006;41(1):37-43.
2005: Rob E Aarnoutse; Johanneke Kleinnijenhuis; Peter P Koopmans; Daan J Touw; Jaap Wieling; Yechiel A Hekster; David Burger
Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Clinical pharmacology and therapeutics 2005;78(6):664-74.
2005: Robert Colebunders; Beata Hodossy; David Burger; Tania Daems; Kristien Roelens; Marc Coppens; Ben Van Bulck; Yves Jacquemyn; Eric Van Wijngaerden; Katrien Fransen
The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk.
AIDS (London, England) 2005;19(16):1912-5.
2005: Reshma Saskia Autar; Marta Boffito; Elly A M Hassink; Ferdinand W N M Wit; Jintanat Ananworanich; Umaporn Siangphoe; Anton Pozniak; David A Cooper; Praphan Phanuphak; Joep M A Lange; Kiat Ruxrungtham; David Burger
Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients.
The Journal of antimicrobial chemotherapy 2005;56(5):908-13.
2005: Jintanat Ananworanich; Pope Kosalaraksa; Andrew Hill; Umaporn Siangphoe; Alina S Bergshoeff; Chitsanu Pancharoen; Chulapan Engchanil; Kiat Ruxrungtham; David Burger
Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.
The Pediatric infectious disease journal 2005;24(10):874-9.
2005: Jacqueline A H Droste; Peter P Koopmans; Yechiel A Hekster; David Burger
TDM: therapeutic drug measuring or therapeutic drug monitoring?
Therapeutic drug monitoring 2005;27(4):412-6.
2005: Eva Muro; Jacqueline A H Droste; Hadewych Ter Hofstede; Marjolein Bosch; Wil Dolmans; David Burger
Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies.
Journal of acquired immune deficiency syndromes (1999) 2005;39(4):419-21.
2005: David J Back; David Burger; Charles Flexner; John G Gerber
The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing.
Journal of acquired immune deficiency syndromes (1999) 2005;39 Suppl 1():S1-23, quiz S24-25.
2005: Charles J L la Porte; Emile F Schippers; Marchina E Van Der Ende; Peter P Koopmans; Willem L Blok; Robbert H Kauffmann; Frank P Kroon; David Burger
Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications.
AIDS (London, England) 2005;19(10):1105-7.
2005: Joep J G van Oosterhout; Neena Bodasing; Johnstone J Kumwenda; Cooper Nyirenda; Jane Mallewa; Paul R Cleary; Michel P De Baar; Rob Schuurman; David Burger; Eduard E Zijlstra
Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.
Tropical medicine & international health : TM & IH 2005;10(5):464-70.
2005: Alina S Bergshoeff; Pieter L A Fraaij; Jennifer Ndagijimana; Gwenda Verweel; Nico G Hartwig; Tim Niehues; Ronald de Groot; David Burger
Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.
Journal of acquired immune deficiency syndromes (1999) 2005;39(1):63-8.
2005: Carmina R Fumaz; Jose Munoz-Moreno; José Moltó; Eugenia Negredo; Maria José Ferrer; Guillem Sirera; Núria Pérez-Alvarez; Guadalupe Gómez; David Burger; Bonaventura Clotet
Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.
Journal of acquired immune deficiency syndromes (1999) 2005;38(5):560-5.
2005: C P W G M Verweij-van Wissen; Rob E Aarnoutse; David Burger
Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005;816(1-2):121-9.
2005: Pieter L A Fraaij; Gwenda Verweel; Annemarie M C van Rossum; Ellen G van Lochem; Martin Schutten; Corry M R Weemaes; Nico G Hartwig; David Burger; Ronald de Groot
Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;40(4):604-8.
2005: Jacqueline A H Droste; C P W G M Verweij-van Wissen; B P Kearney; R Buffels; P J Vanhorssen; Yechiel A Hekster; David Burger
Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.
Antimicrobial agents and chemotherapy 2005;49(2):680-4.
2005: Charles J L la Porte; C P W G M Verweij-van Wissen; N van Ewijk; Rob E Aarnoutse; Peter P Koopmans; Peter Reiss; Michael Stek; Yechiel A Hekster; David Burger
Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers.
Journal of clinical pharmacology 2005;45(2):211-8.
2005: Reshma Saskia Autar; Ferdinand W N M Wit; Jongkol sankote; Apicha Mahanontharit; Thanomsak Anekthananon; Piroon Mootsikapun; Khanjtta Sujaikaew; David A Cooper; Joep M A Lange; Praphan Phanuphak; Kiat Ruxrungtham; David Burger
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.
Antiviral therapy 2005;10(8):937-43.
2005: Jolando G M Hoefnagel; Peter P Koopmans; David Burger; Rob Schuurman; Jochem M D Galama
Role of the inhibitory quotient in HIV therapy.
Antiviral therapy 2005;10(8):879-92.
2005: Pieter L A Fraaij; Jeroen J A van Kampen; David Burger; Ronald de Groot
Pharmacokinetics of antiretroviral therapy in HIV-1-infected children.
Clinical pharmacokinetics 2005;44(9):935-56.
2005: Marta Boffito; Edward Acosta; David Burger; Courtney V Fletcher; Charles Flexner; Rodolphe Garaffo; Giorgio Gatti; Michael Kurowski; Carlo Federico Perno; Gilles Peytavin; Mario Regazzi; David Back
Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs.
Antiviral therapy 2005;10(4):469-77.
2005: Marta Boffito; Edward Acosta; David Burger; Courtney V Fletcher; Charles Flexner; Rodolphe Garaffo; Giorgio Gatti; Michael Kurowski; Carlo Federico Perno; Gilles Peytavin; Mario Regazzi; David Back
Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy.
Antiviral therapy 2005;10(3):375-92.
2005: Mark Boyd; Piroon Mootsikapun; David Burger; Theshinee Chuenyam; Sasiwimol Ubolyam; Apicha Mahanontharit; Jongkol Sangkote; Parichart Bunyaprawit; Manasinee Horsakulchai; Joep Lange; David Cooper; Praphan Phanuphak; Kiat Ruxrungtham
Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
Antiviral therapy 2005;10(2):301-7.
2005: Alina S Bergshoeff; David Burger; Corrien Verweij; Laura Farrelly; Jacquie Flynn; Marthe Le Prevost; Sarah Walker; Vas Novelli; Hermione Lyall; Saye Khoo; Diana M Gibb
Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).
Antiviral therapy 2005;10(2):239-46.
2005: Eugenia Negredo; José Moltó; David Burger; Helene Côté; Oscar Miró; Josep Ribalta; Eva Martínez; Jordi Puig; Lidia Ruiz; Juliana Salazar; Sònia López; Julio Montaner; Celestino Rey-Joly; Bonaventura Clotet
Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
Journal of acquired immune deficiency syndromes (1999) 2005;38(1):47-52.
2004: David Burger; Andre J A M van der Ven; P P Koopmans
Highly active antiretroviral therapy for HIV infection: lessons for the future.
The Netherlands journal of medicine 2004;62(11):407-8.
2004: Charles J L la Porte; M J A de Graaff-Teulen; E P H Colbers; D S Voncken; S Marco Ibanez; Peter P Koopmans; Yechiel A Hekster; David Burger
Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers.
British journal of clinical pharmacology 2004;58(6):632-40.
2004: Alina S Bergshoeff; Pieter L A Fraaij; Corrien Verweij; Annemarie M C van Rossum; Gwenda Verweel; Nico G Hartwig; Ronald de Groot; David Burger
Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children.
The Journal of antimicrobial chemotherapy 2004;54(6):1152-4.
2004: David Burger; Karin J T Grintjes; Fred K Lotgering; Peter P Koopmans
Therapeutic drug monitoring of nelfinavir in pregnancy: a case report.
Therapeutic drug monitoring 2004;26(5):576-8.
2004: Reshma Saskia Autar; Jintanat Ananworanich; Wichitra Apateerapong; Jongkol sankote; Andrew Hill; Bernard Hirschel; David Cooper; Joep Lange; Praphan Phanuphak; Kiat Ruxrungtham; David Burger
Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.
The Journal of antimicrobial chemotherapy 2004;54(4):785-90.
2004: Jeannine F J B Nellen; Igor Schillevoort; Ferdinand W N M Wit; Alina S Bergshoeff; Mieke H Godfried; Kees Boer; Joep M A Lange; David Burger; Jan M Prins
Nelfinavir plasma concentrations are low during pregnancy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(5):736-40.
2004: David Burger; Alina S Bergshoeff; Ronald de Groot; Diana M Gibb; Sarah Walker; Jean-Marc Tréluyer; Richard Hoetelmans
Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.
The Journal of pediatrics 2004;145(3):403-5.
2004: Eugenia Negredo; José Moltó; Jose Munoz-Moreno; Enric Pedrol; Esteban Ribera; Pompeyo E. Viciana; M José Galindos; Celia Miralles; David Burger; Carmina Rodriguez Fumaz; Jordi Puig; Silvia Gel; Eva Rodríguez; Sebastián Videla; Lidia Ruiz; Bonaventura Clotet
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
Antiviral therapy 2004;9(3):335-42.
2004: Alina S Bergshoeff; Pieter L A Fraaij; Annemarie M C van Rossum; Gwenda Verweel; L H Wynne; G A Winchell; R Y Leavitt; Bach-Yen Nguyen; Ronald de Groot; David Burger
Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.
Antimicrobial agents and chemotherapy 2004;48(5):1904-7.
2004: Charles J L la Porte; E P H Colbers; R Bertz; D S Voncken; K Wikstrom; Martin J Boeree; Peter P Koopmans; Yechiel A Hekster; David Burger
Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers.
Antimicrobial agents and chemotherapy 2004;48(5):1553-60.
2004: Pieter L A Fraaij; Natella Rakhmanina; David Burger; Ronald de Groot
Therapeutic drug monitoring in children with HIV/AIDS.
Therapeutic drug monitoring 2004;26(2):122-6.
2004: Reinout van Crevel; R H H Nelwan; F Borst; Edhyana Sahiratmadja; J Cox; W van der Meij; M de Graaff; Alisjahbana Bachti; W C M de Lange; David Burger
Bioavailability of rifampicin in Indonesian subjects: a comparison of different local drug manufacturers.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2004;8(4):500-3.
2004: Pieter L A Fraaij; Jennifer Neubert; Alina S Bergshoeff; Annemarie M C van Rossum; Nico G Hartwig; Horst Schroten; Klaus Korn; David Burger; Ronald de Groot; Tim Niehues
Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.
Antiviral therapy 2004;9(2):297-9.
2004: Jan-Christian Wasmuth; Charles J L la Porte; Katrin Schneider; David Burger; Jürgen K Rockstroh
Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR).
Antiviral therapy 2004;9(2):213-20.
2004: Rob E Aarnoutse; Kees Brinkman; Jorge Benetucci; Josip Begovac; Michael Stek; David Burger
Pharmacokinetics of indinavir/ritonavir (800/100 mg twice a day) combined with efavirenz in HIV-infected patients.
AIDS (London, England) 2004;18(3):565-7.
2004: Eugenia Negredo; José Moltó; David Burger; Pompeyo E. Viciana; Esteban Ribera; Roger Paredes; Manel Juan; Lidia Ruiz; Jordi Puig; Alain Pruvost; Jacques Grassi; Elisabeth Masmitjà; Bonaventura Clotet
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
AIDS (London, England) 2004;18(3):459-63.
2004: David Burger; Jan M Prins; Marchina E Van Der Ende; Rob E Aarnoutse
The effect of nevirapine on the pharmacokinetics of indinavir/ritonavir 800/100 mg BID.
Journal of acquired immune deficiency syndromes (1999) 2004;35(1):97-8.
2003: Hadewych J M ter Hofstede; David Burger; Peter P Koopmans
Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity.
The Netherlands journal of medicine 2003;61(12):393-403.
2003: David Burger; Rob E Aarnoutse; Jeanne P Dieleman; Inge C Gyssens; Jan Nouwen; Siem de Marie; Peter P Koopmans; Michael Stek; Marchina E Van Der Ende
A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
Antiviral therapy 2003;8(5):455-61.
2003: Mark A Boyd; Rob E Aarnoutse; Kiat Ruxrungtham; Michael Stek; Rolf P G van Heeswijk; Joep M A Lange; David A Cooper; Praphan Phanuphak; David Burger
Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.
Journal of acquired immune deficiency syndromes (1999) 2003;34(2):134-9.
2003: Pieter L A Fraaij; Alina S Bergshoeff; Annemarie M C van Rossum; Nico G Hartwig; David Burger; Ronald de Groot
Changes in indinavir exposure over time: a case study in six HIV-1-infected children.
The Journal of antimicrobial chemotherapy 2003;52(4):727-30.
2003: Rob E Aarnoutse; Jan-Christian Wasmuth; Gerd Fätkenheuer; Katrin Schneider; Karina Schmitz; Theo M de Boo; Peter Reiss; Yechiel A Hekster; David Burger; Jürgen K Rockstroh
Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
Antiviral therapy 2003;8(4):309-14.
2003: Charles J L la Porte; Jan-Christian Wasmuth; Katrin Schneider; Jürgen K Rockstroh; David Burger
Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy.
AIDS (London, England) 2003;17(11):1700-2.
2003: Peter Cardiello; Tarika Samor; David Burger; Richard Hoetelmans; Apicha Mahanontharit; Kiat Ruxrungtham; Joep M A Lange; David A Cooper; Praphan Phanuphak
Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients.
Antiviral therapy 2003;8(3):245-9.
2003: Alina S Bergshoeff; Pieter L A Fraaij; Annemarie M C van Rossum; Tom F W Wolfs; S P M Geelen; Ronald de Groot; David Burger
Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.
Antiviral therapy 2003;8(3):215-22.
2003: Jacqueline A H Droste; C P W G M Verweij-van Wissen; David Burger
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.
Therapeutic drug monitoring 2003;25(3):393-9.
2003: David Burger; Patricia W H Hugen; Peter Reiss; Inge C Gyssens; Margriet Schneider; Frank P Kroon; Gerrit Schreij; Kees Brinkman; Clemens Richter; Jan Prins; Rob E Aarnoutse; Joep Lange
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.
AIDS (London, England) 2003;17(8):1157-65.
2003: David Burger; Mark Boyd; Chris Duncombe; Mariet Felderhof; Apicha Mahanontharit; Kiat Ruxrungtham; Sasiwimol Ubolyam; Michael Stek; David Cooper; Joep Lange; Praphan Phanupak; Peter Reiss
Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.
The Journal of antimicrobial chemotherapy 2003;51(5):1231-8.
2003: Juan A Arnaiz; Josep Mallolas; Daniel Podzamczer; Jan Gerstoft; Jens D Lundgren; Pedro Cahn; Gerd Fätkenheuer; Antonella d'Arminio Monforte; Arnaldo Casiró; Peter Reiss; David Burger; Michael Stek; José M Gatell
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
AIDS (London, England) 2003;17(6):831-40.
2003: Alina S Bergshoeff; Tom F W Wolfs; S P M Geelen; David Burger
Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.
The Annals of pharmacotherapy 2003;37(4):521-5.
2003: Peter Cardiello; Tarkika Monhaphol; Apicha Mahanontharit; Rolf P G van Heeswijk; David Burger; Andrew Hill; Kiat Ruxrungtham; Joep M A Lange; David A Cooper; Praphan Phanuphak
Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.
Journal of acquired immune deficiency syndromes (1999) 2003;32(4):375-9.
2003: J J G van Oosterhout; Martin J Boeree; David Burger; W C M de Lange; Reinout van Crevel; Peter P Koopmans
[Tuberculosis and HIV coinfection in three patients: the possibilities for simultaneous treatment].
Nederlands tijdschrift voor geneeskunde 2003;147(9):369-72.
2003: Jacqueline A H Droste; Rob E Aarnoutse; Peter P Koopmans; Yechiel A Hekster; David Burger
Evaluation of antiretroviral drug measurements by an interlaboratory quality control program.
Journal of acquired immune deficiency syndromes (1999) 2003;32(3):287-91.
2003: Rob E Aarnoutse; Jacqueline A H Droste; J J G van Oosterhout; Peter P Koopmans; M Popescu; Peter Reiss; Yechiel A Hekster; David Burger
Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers.
British journal of clinical pharmacology 2003;55(2):115-25.
2003: Jeanne P Dieleman; Annemarie M C van Rossum; Bruno C H Stricker; Miriam C J M Sturkenboom; Ronald de Groot; Denise S C Telgt; Willem L Blok; David Burger; Bert G Blijenberg; Robert Zietse; Inge C Gyssens
Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir.
Journal of acquired immune deficiency syndromes (1999) 2003;32(2):135-42.
2003: David Burger; Patricia W H Hugen; Rob E Aarnoutse; Richard Hoetelmans; Marielle Jambroes; Pythia T Nieuwkerk; Gerrit Schreij; M M E Schneider; Marchina E Van Der Ende; Joep M A Lange
Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations.
Therapeutic drug monitoring 2003;25(1):73-80.
2003: Rob E Aarnoutse; Jonathan M Schapiro; Charles A B Boucher; Yechiel A Hekster; David Burger
Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?
Drugs 2003;63(8):741-53.
2002: Patricia W H Hugen; David Burger; Rob E Aarnoutse; Patricia A Baede; Pythia T Nieuwkerk; Peter P Koopmans; Yechiel A Hekster
Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance.
Therapeutic drug monitoring 2002;24(5):579-87.
2002: Sanjay U C Sankatsing; Jacqueline A H Droste; David Burger; Rieneke van Praag; Suzanne Jurriaans; Joep M A Lange; Jan M Prins
Limited penetration of lopinavir into seminal plasma of HIV-1-infected men.
AIDS (London, England) 2002;16(12):1698-700.
2002: Annemarie M C van Rossum; Alina S Bergshoeff; Pieter L A Fraaij; Patricia W H Hugen; Nico G Hartwig; S P M Geelen; Tom F W Wolfs; Corry M R Weemaes; Ronald de Groot; David Burger
Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.
The Pediatric infectious disease journal 2002;21(8):743-7.
2002: Annemarie M C van Rossum; Jeanne P Dieleman; Pieter L A Fraaij; Karlien Cransberg; Nico G Hartwig; David Burger; Inge C Gyssens; Ronald de Groot
Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir.
Pediatrics 2002;110(2 Pt 1):e19.
2002: Patricia W H Hugen; Nienke Langebeek; David Burger; Bert Zomer; Rob van Leusen; Rob Schuurman; Peter P Koopmans; Yechiel A Hekster
Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring.
Journal of acquired immune deficiency syndromes (1999) 2002;30(3):324-34.
2002: Patricia W H Hugen; David Burger; Peter P Koopmans; J W T Cohen Stuart; Frank P Kroon; Rob van Leusen; Yechiel A Hekster
Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfast.
Pharmacy world & science : PWS 2002;24(3):83-6.
2002: Reinout van Crevel; Alisjahbana Bachti; W C M de Lange; F Borst; Halim Danusantoso; J W M Van Der Meer; David Burger; R H H Nelwan
Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2002;6(6):497-502.
2002: Annemarie M C van Rossum; S P M Geelen; Nico G Hartwig; Tom F W Wolfs; Corry M R Weemaes; Henriëtte J Scherpbier; Ellen G van Lochem; Wim C J Hop; Martin Schutten; Albert D M E Osterhaus; David Burger; Ronald de Groot
Results of 2 years of treatment with protease-inhibitor--containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;34(7):1008-16.
2002: Rob E Aarnoutse; C P W G M Verweij-van Wissen; Eleonora W J van Ewijk-Beneken Kolmer; Eveline W Wuis; Peter P Koopmans; Yechiel A Hekster; David Burger
International interlaboratory quality control program for measurement of antiretroviral drugs in plasma.
Antimicrobial agents and chemotherapy 2002;46(3):884-6.
2002: David Burger; Rob E Aarnoutse; Patricia W H Hugen
Pros and cons of therapeutic drug monitoring of antiretroviral agents.
Current opinion in infectious diseases 2002;15(1):17-22.
2002: Rolf P G van Heeswijk; James W T Cohen Stuart; David Burger; Jos H Beijnen; Jan C C Borleffs; Richard Hoetelmans
Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study.
British journal of clinical pharmacology 2002;53(2):211-2.
2002: Rob E Aarnoutse; Karin J T Grintjes; Denise S C Telgt; Michael Stek; Patricia W H Hugen; Peter Reiss; Peter P Koopmans; Yechiel A Hekster; David Burger
The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
Clinical pharmacology and therapeutics 2002;71(1):57-67.
2002: David Burger; Marijke C Siebers; Patricia W H Hugen; Rob E Aarnoutse; Yechiel A Hekster; Peter P Koopmans
Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men?
Journal of acquired immune deficiency syndromes (1999) 2002;29(1):101-2.
2001: R E Aarnoutse; C P W G M Verweij-van Wissen; W J Underberg; Johanneke Kleinnijenhuis; Yechiel A Hekster; David Burger
High-performance liquid chromatography of HIV protease inhibitors in human biological matrices.
Journal of chromatography. B, Biomedical sciences and applications 2001;764(1-2):363-84.
2001: Gerd Fätkenheuer; Katja Römer; R Kamps; Bernd Salzberger; David Burger
Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.
AIDS (London, England) 2001;15(17):2334-5.
2001: Pythia T Nieuwkerk; Mirjam A G Sprangers; David Burger; Richard Hoetelmans; Patricia W H Hugen; Sven A Danner; Marchina E Van Der Ende; M M E Schneider; G Schrey; Pieter L Meenhorst; Herman Sprenger; Robbert H Kauffmann; Marielle Jambroes; Margaret A Chesney; Frank de Wolf; Joep M A Lange
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
Archives of internal medicine 2001;161(16):1962-8.
2001: Jeanne P Dieleman; Saima Salahuddin; Y S Hsu; David Burger; Inge C Gyssens; Miriam C J M Sturkenboom; Bruno H Ch Stricker; dirk kok
Indinavir crystallization around the loop of Henle: experimental evidence.
Journal of acquired immune deficiency syndromes (1999) 2001;28(1):9-13.
2001: Cornelis H W Koks; Kristel M L Crommentuyn; Richard Hoetelmans; David Burger; P P Koopmans; Ron A A Mathôt; Jan W Mulder; Pieter L Meenhorst; Jos H Beijnen
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
British journal of clinical pharmacology 2001;51(6):631-5.
2001: P A Baede-van Dijk; Patricia W H Hugen; C P W G M Verweij-van Wissen; Peter P Koopmans; David Burger; Yechiel A Hekster
Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.
AIDS (London, England) 2001;15(8):991-8.
2001: NA Foudraine; Suzanne Jurriaans; Gerrit Jan Weverling; David Burger; Richard Hoetelmans; Marijke Th L Roos; JJ Maas; Frank Miedema; Peter Reiss; Peter Portegies; Frank de Wolf; Joep M A Lange
Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
Antiviral therapy 2001;6(1):55-62.
2001: David Burger; Patricia W H Hugen; Rob E Aarnoutse; Jeanne P Dieleman; J M Prins; T van der Poll; Jacob H Ten Veen; Jan W Mulder; Pieter L Meenhorst; Willem L Blok; J T van der Meer; Peter Reiss; Joep M A Lange
A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy.
Journal of acquired immune deficiency syndromes (1999) 2001;26(3):218-24.
2001: David Burger; Annemarie M C van Rossum; Patricia W H Hugen; MH Suur; Nico G Hartwig; S P M Geelen; Henriëtte J Scherpbier; Richard Hoetelmans; Arnold G Vulto; Ronald de Groot
Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.
Antimicrobial agents and chemotherapy 2001;45(3):701-5.
2000: Emile F Schippers; Patricia W H Hugen; Jan den Hartigh; David Burger; Richard Hoetelmans; Leo G Visser; Frank P Kroon
No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients.
AIDS (London, England) 2000;14(17):2794-5.
2000: David Burger; Patricia W H Hugen; Marchina E Van Der Ende; P van Wijngaarden; Rob E Aarnoutse; Peter Reiss; Joep M A Lange
Once-daily indinavir plus ritonavir: preliminary results of the PIPO study.
AIDS (London, England) 2000;14(16):2621-3.
2000: Patricia W H Hugen; David Burger; Hadewych J M ter Hofstede; Peter P Koopmans; Michael Stek; Yechiel A Hekster; Peter Reiss; Joep M A Lange
Dose-finding study of a once-daily indinavir/ritonavir regimen.
Journal of acquired immune deficiency syndromes (1999) 2000;25(3):236-45.
2000: Albert Tuldrà; Carmina R Fumaz; Maria José Ferrer; Ramon Bayés; Albert Arno; Montserrat Balagué; Anna Bonjoch; Antoni Jou; Eugenia Negredo; Roger Paredes; Lidia Ruiz; Joan Romeu; Guillem Sirera; Cristina Tural; David Burger; Bonaventura Clotet
Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2000;25(3):221-8.
2000: Annemarie M C van Rossum; R de Groot; Nico G Hartwig; Corry M R Weemaes; S Head; David Burger
Pharmacokinetics of indinavir and low-dose ritonavir in children with HIV-1 infection.
AIDS (London, England) 2000;14(14):2209-10.
2000: Patricia W H Hugen; David Burger; M de Graaff; Hadewych J M ter Hofstede; Richard Hoetelmans; Kees Brinkman; Pieter L Meenhorst; Jan W Mulder; Peter P Koopmans; Yechiel A Hekster
Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir.
Therapeutic drug monitoring 2000;22(4):437-45.
2000: Patricia W H Hugen; David Burger; Hadewych J M ter Hofstede; Peter P Koopmans; Yechiel A Hekster
Development of an indinavir oral liquid for children.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2000;57(14):1332-9.
2000: R M Hollanders; Eleonora W J van Ewijk-Beneken Kolmer; David Burger; Eveline W Wuis; Peter P Koopmans; Yechiel A Hekster
Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2000;744(1):65-71.
2000: Rieneke van Praag; Gerrit Jan Weverling; Peter Portegies; Suzanne Jurriaans; X J Zhou; M L Turner-Foisy; Jean-Pierre Sommadossi; David Burger; Joep M A Lange; Richard Hoetelmans; Jan M Prins
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
AIDS (London, England) 2000;14(9):1187-94.
2000: Annemarie M C van Rossum; Hubert G M Niesters; S P M Geelen; Henriëtte J Scherpbier; Nico G Hartwig; Corry M R Weemaes; A J Veerman; MH Suur; Elisabeth R De Graeff-Meeder; WA Slieker; Wim C J Hop; Albert D M E Osterhaus; David Burger; Ronald de Groot
Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children with HIV-1 infections.
The Journal of pediatrics 2000;136(6):780-8.
2000: Patricia W H Hugen; David Burger; Kees Brinkman; Hadewych J M ter Hofstede; R Schuurman; Peter P Koopmans; Yechiel A Hekster
Carbamazepine--indinavir interaction causes antiretroviral therapy failure.
The Annals of pharmacotherapy 2000;34(4):465-70.
1999: Eveline W Wuis; David Burger; M Beelen; Yechiel A Hekster
Stability of dithranol in creams.
Pharmacy world & science : PWS 1999;21(6):275-7.
1999: Albert Tuldrà; Maria José Ferrer; Carmina R Fumaz; Ramon Bayés; R Paredes; David Burger; Bonaventura Clotet
Monitoring adherence to HIV therapy.
Archives of internal medicine 1999;159(12):1376-7.
1999: C M Essink-Tjebbes; David Burger; M Beelen; Eveline W Wuis; Yechiel A Hekster
Long-term stability of morphine and bupivacaine mixture for spinal use.
Pharmacy world & science : PWS 1999;21(3):144-6.
1999: James W T Cohen Stuart; Rob Schuurman; David Burger; Peter P Koopmans; Herman Sprenger; Job R Juttmann; Clemens Richter; Pieter L Meenhorst; Richard Hoetelmans; Frank P Kroon; B Bravenboer; Dörte Hamann; Charles A B Boucher; Jan C C Borleffs
Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
AIDS (London, England) 1999;13(7):F53-8.
1999: Patricia W H Hugen; C P W G M Verweij-van Wissen; David Burger; Eveline W Wuis; Peter P Koopmans; Yechiel A Hekster
Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1999;727(1-2):139-49.
1999: Jeanne P Dieleman; Inge C Gyssens; Marchina E Van Der Ende; Siem de Marie; David Burger
Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients.
AIDS (London, England) 1999;13(4):473-8.
1998: Peter P Koopmans; David Burger
Managing drug reactions to sulfonamides and other drugs in HIV infection: desensitization rather than rechallenge?
Pharmacy world & science : PWS 1998;20(6):253-7.
1998: Kees Brinkman; F Huysmans; David Burger
Pharmacokinetic interaction between saquinavir and cyclosporine.
Annals of internal medicine 1998;129(11):914-5.
1998: David Burger; Patricia W H Hugen; Frank P Kroon; Paul H P Groeneveld; Kees Brinkman; NA Foudraine; Herman Sprenger; Peter P Koopmans; Yechiel A Hekster
Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir.
AIDS (London, England) 1998;12(15):2080-2.
1998: Roelien H Enting; Richard Hoetelmans; Joep M A Lange; David Burger; J H Beijnen; Peter Portegies
Antiretroviral drugs and the central nervous system.
AIDS (London, England) 1998;12(15):1941-55.
1998: Kees Brinkman; Hadewych J M ter Hofstede; David Burger; Jan A M Smeitink; Peter P Koopmans
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway.
AIDS (London, England) 1998;12(14):1735-44.
1998: Lidia Ruiz; Monique Nijhuis; C Boucher; Teresa Puig; Anna Bonjoch; Javier Martínez-Picado; Silvia Marfil; D de Jong; David Burger; Albert Arno; Montserrat Balagué; Bonaventura Clotet
Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998;19(1):19-28.
1998: Kees Brinkman; Frank P Kroon; Patricia W H Hugen; David Burger
Therapeutic concentrations of indinavir in cerebrospinal fluid of HIV-1-infected patients.
AIDS (London, England) 1998;12(5):537.
1998: David Burger; Richard Hoetelmans; Patricia W H Hugen; Jan W Mulder; Pieter L Meenhorst; Peter P Koopmans; Kees Brinkman; M Keuter; Wil M V Dolmans; Yechiel A Hekster
Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy.
Antiviral therapy 1998;3(4):215-20.
1997: David Burger; M de Graaff; Eveline W Wuis; Peter P Koopmans; Yechiel A Hekster
Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1997;703(1-2):235-41.
1997: Richard Hoetelmans; Pieter L Meenhorst; Jan W Mulder; David Burger; Cornelis H W Koks; Jos H Beijnen
Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
Pharmacy world & science : PWS 1997;19(4):159-75.
1997: David Burger; Richard Hoetelmans; Peter P Koopmans; Pieter L Meenhorst; Jan W Mulder; Yechiel A Hekster; J H Beijnen
Clinically relevant drug interactions with antiretroviral agents.
Antiviral therapy 1997;2(3):149-65.
1997: Richard Hoetelmans; C L Kraaijeveld; Pieter L Meenhorst; Jan W Mulder; David Burger; Cornelis H W Koks; J H Beijnen
Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;15(2):131-6.
1997: David Burger; C A Boucher; Pieter L Meenhorst; C L Kraayeveld; Peter Portegies; Jan W Mulder; Richard Hoetelmans; J H Beijnen
HIV-1 RNA levels in the cerebrospinal fluid may increase owing to damage to the blood-brain barrier.
Antiviral therapy 1997;2(2):113-7.
1996: C A Eggink; W Vaandrager; David Burger; R W Sauerwein
[Acanthamoeba keratitis].
Nederlands tijdschrift voor geneeskunde 1996;140(21):1130-33.
1996: Richard Hoetelmans; David Burger; Pieter L Meenhorst; Jos H Beijnen
Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.
Clinical pharmacokinetics 1996;30(4):314-27.
1995: David Burger; C L Kraayeveld; Pieter L Meenhorst; Jan W Mulder; Richard Hoetelmans; Cornelis H W Koks; Jos H Beijnen
Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex.
Pharmacy world & science : PWS 1995;17(6):218-21.
1995: David Burger; Pieter L Meenhorst; J Mulder; J Henrichs; J Frissen; F Kroon; C ten Napel; K Koks; A Bult; Jos H Beijnen
Substitution of didanosine sachets by chewable tablets: a pharmacokinetic study in patients with AIDS.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;10(2):163-8.
1995: David Burger; Pieter L Meenhorst; Jos H Beijnen
Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents.
Pharmacy world & science : PWS 1995;17(2):25-30.
1994: David Burger; Pieter L Meenhorst; C H ten Napel; Jan W Mulder; C Neef; Cornelis H W Koks; A Bult; Jos H Beijnen
Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions.
AIDS (London, England) 1994;8(12):1683-9.
1994: David Burger; Pieter L Meenhorst; Jan W Mulder; C L Kraaijeveld; Cornelis H W Koks; A Bult; Jos H Beijnen
Therapeutic drug monitoring of phenytoin in patients with the acquired immunodeficiency syndrome.
Therapeutic drug monitoring 1994;16(6):616-20.
1994: David Burger; Hilde Rosing; C H ten Napel; T Duyts; Pieter L Meenhorst; Jan W Mulder; Cornelis H W Koks; A Bult; Jos H Beijnen
Application of a radioimmunoassay for determination of levels of zalcitabine (ddC) in human plasma, urine, and cerebrospinal fluid.
Antimicrobial agents and chemotherapy 1994;38(12):2763-7.
1994: David Burger; Pieter L Meenhorst; Willy J M Underberg; J F van der Heijde; Cornelis H W Koks; J H Beijnen
Short-term, combined use of paracetamol and zidovudine does not alter the pharmacokinetics of either drug.
The Netherlands journal of medicine 1994;44(5):161-5.
1994: David Burger; Pieter L Meenhorst; Cornelis H W Koks; Jos H Beijnen
Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy.
The Annals of pharmacotherapy 1994;28(3):327-30.
1993: David Burger; Hilde Rosing; FJ Koopman; P L Mennhorst; Jan W Mulder; A Bult; Jos H Beijnen
Determination of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of 3'-azido-3'-deoxythymidine, in human plasma by ion-pair high-performance liquid chromatography.
Journal of chromatography 1993;622(2):235-42.
1993: David Burger; C L Kraaijeveld; Pieter L Meenhorst; Jan W Mulder; Cornelis H W Koks; A Bult; Jos H Beijnen
Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV.
AIDS (London, England) 1993;7(12):1581-7.
1993: David Burger; E A van Dijk; R van Gijn; J H Beijnen
Effect of heat treatment of potentially infected blood samples on therapeutic drug monitoring of selected drugs.
The Annals of pharmacotherapy 1993;27(7-8):887-8.
1993: David Burger; Pieter L Meenhorst; Cornelis H W Koks; Jos H Beijnen
Pharmacokinetic interaction between rifampin and zidovudine.
Antimicrobial agents and chemotherapy 1993;37(7):1426-31.
1993: O Bekers; Jos H Beijnen; M J Tank; David Burger; Pieter L Meenhorst; A J Lombarts; Willy J M Underberg
2',3'-dideoxyinosine (ddI): its chemical stability and cyclodextrin complexation in aqueous media.
Journal of pharmaceutical and biomedical analysis 1993;11(6):489-93.
1993: W J Keijer; David Burger; G H Neuteboom; J L Vrooland; Pieter L Meenhorst; Cornelis H W Koks; Jos H Beijnen
Ocular complications of the acquired immunodeficiency syndrome. Focus on the treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Pharmacy world & science : PWS 1993;15(2):56-67.
1993: David Burger; Pieter L Meenhorst; Cornelis H W Koks; J H Beijnen
Drug interactions with zidovudine.
AIDS (London, England) 1993;7(4):445-60.
1992: David Burger; Hilde Rosing; R van Gijn; Pieter L Meenhorst; Olaf van Tellingen; Jos H Beijnen
Determination of stavudine, a new antiretroviral agent, in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography 1992;584(2):239-47.
1991: David Burger; Yechiel A Hekster; W P Hopman; R Does
Omeprazole. A pharmaco-epidemiological study of its use in a university hospital.
Pharmaceutisch weekblad. Scientific edition 1991;13(5):215-9.
1991: AH Mulder; David Burger; George Wardeh; Francois Hogenboom; A L Frankhuyzen
Pharmacological profile of various kappa-agonists at kappa-, mu- and delta-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the rat brain.
British journal of pharmacology 1991;102(2):518-22.